Abstract
MDR-TB patients treated with 6 months or more of delamanid had significantly lower likelihood of mortality http://ow.ly/HOv1d
Publication types
-
Letter
-
Randomized Controlled Trial
MeSH terms
-
Biomarkers
-
Follow-Up Studies
-
Humans
-
Mycobacterium tuberculosis
-
Nitroimidazoles / therapeutic use*
-
Oxazoles / therapeutic use*
-
Prospective Studies
-
Treatment Outcome
-
Tuberculosis, Multidrug-Resistant / drug therapy*
-
Tuberculosis, Multidrug-Resistant / mortality*
Substances
-
Biomarkers
-
Nitroimidazoles
-
OPC-67683
-
Oxazoles